AUS
NZ
UK
CA
USA
IND
Highlights
- Liabilities of Little Green Pharma (ASX:LGP) are manageable given its market capitalization.
- The company holds more cash than debt, indicating a stable financial position.
- Little Green Pharma's balance sheet suggests no immediate significant risks.
When assessing the financial risk associated with any stock, it's crucial to consider the debt levels. As the renowned fund manager Li Lu pointed out, the greatest investment peril isn't price volatility but the potential for a permanent loss of capital. For Little Green Pharma Ltd (ASX:LGP), an evaluation of debt is essential in determining its financial health.
Understanding Debt Risks
Debt can power business growth, yet it becomes a concern when a company cannot meet its financial obligations. This may lead to bankruptcy or necessitate raising new equity at a low cost, consequently impacting shareholders. However, many companies effectively utilize debt without adverse outcomes. Examining both debt and cash reserves offers insight into a company's financial practices.
Little Green Pharma's Financial Standing
As of September 2024, Little Green Pharma had reduced its debt to AU$3.29 million from AU$5.64 million the previous year and held AU$4.83 million in cash, resulting in net cash of AU$1.54 million. This indicates a healthy balance between debt and cash reserves.
On analyzing the balance sheet, liabilities of AU$7.94 million are due within a year, with another AU$2.53 million due afterwards. These are offset by AU$4.83 million in cash and AU$2.23 million in receivables, leaving AU$3.40 million more in liabilities than readily available financial resources.
Considering the company's market capitalization of AU$31.8 million, these liabilities seem manageable. Despite the noteworthy liabilities, the net cash position suggests that Little Green Pharma isn't burdened by excessive debt.
Revenue and Growth Prospects
For the past 12 months, Little Green Pharma reported AU$29 million in revenue, marking a 16% increase. Though the company hasn't shown positive earnings before interest and tax (EBIT), it did generate a free cash flow of AU$1.2 million, mitigating near-term balance sheet risks.
While earnings have yet to demonstrate substantial growth, the company's stable balance sheet, including its net cash position, suggests a level of security, albeit with cautious optimism for future revenue growth.
Despite the lack of significant earnings, Little Green Pharma maintains a promising financial position with more cash than debt. Prospective investors should monitor the balance sheet and revenue trends to gauge long-term potential.
